Skip to content
logo_IFAPP_crop
  • About
    • Mission & Objectives
    • Definition of Pharmaceutical Medicine
    • PharmaTrain Syllabus
    • Governance
      • The Board of Officers
      • The House of Delegates
      • The General Assembly
    • Constitution
    • History
      • Council of Past Presidents
  • News
    • News & Posts
    • IFAPP World Newsletter Past Editions
  • IFAPP TODAY
  • Working Groups
    • Communication
    • Education and Certification
    • Ethics
    • External Affairs
    • Young Professionals
  • Collaborations & Partners
  • Events
  • Members and Individual Affiliates
  • Publications
  • Course Marketplace

EMA and the pharmaceutical industry

By Anna Jurczynska | August 3, 2017

Posted in Recent News and tagged Annual Report of EMA interactions with industry stakeholders, Eligibility criteria, ema, European Commission EU Transparency registry, European Medicines Agency, Framework for interaction, survey
← Concept paper on development and lifecycle of personalised medicines and companion diagnosticsFDA Tackles Drug Competition to Improve Patient Access →

Recent Posts

  • IFAPP TODAY | MAY 2023 | NUMBER 34
  • HTA requirements in relation to the EU Regulation. A German perspective
  • Webinar on Clinical Trials in Paediatrics
  • IFAPP TODAY | APRIL 2023 | NUMBER 33
  • Key Principles for Electronic Product Information in the EU

Categories

  • I am IFAPP
  • Recent News

IFAPP secretariat

Leidsestraatweg 41-D

3443 BP WOERDEN

THE NETHERLANDS

Chamber of Commerce: 30224375

Phone: +31 6 2291 1039

E-mail: secretariat@ifapp.org

Privacy Policy

Cookie Policy

logo_icon

Created By: MDM Creative | ©2019